VI.REL Pharma

Name

VI.REL Pharma

Legal name

VI.REL Pharma S.R.L.

Website

https://virelpharma.it

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory and Pharmacovigilance Consulting

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Management Consulting Services (8742), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

akta.pro secondary industries

Pharmacovigilance, Drug Safety & Risk Management FSP (HLAGAOAF), Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF) (HLAGAKAH), Signal Detection & Safety Analytics (Epidemiology/RWE) (HLAGALAC)

Keywords

• Pharmaceutical consulting
• Pharmacovigilance services
• Regulatory affairs
• Medical writing
• Clinical trial services

Headquarters

HQ city

Turin

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Professional Consultancy Services: VI.REL Pharma generates revenue through specialized pharmaceutical consultancy services including pharmacovigilance system management, regulatory affairs support, medical writing, and clinical trial services. Services are offered both as complete management packages and project-based engagements. The company serves as a service provider meeting diverse client needs from full pharmacovigilance activity management to specific project-based consulting.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

VI.REL Pharma provides specialized pharmaceutical consultancy covering the full product lifecycle from clinical development through post-marketing authorization. Core services include pharmacovigilance system management (QPPV services, ICSR management, signal detection, PSMF, PSUR, risk management plans), regulatory affairs support (marketing authorization applications, Scientific Advice, Orphan Drug Designation), professional medical writing (CTD modules, ERA, scientific publications), and clinical trial pharmacovigilance (DSUR, SUSAR, CSR, CTA) for pharmaceutical companies operating in the EEA, USA, and Asian markets. The firm also operates a VI.REL Master Class training program for individuals and companies.

Product overview

VI.REL Pharma is a pharmaceutical consultancy firm founded in 1997 (with roots dating to 1988) offering specialized services across the product lifecycle from development to commercialization. The core portfolio consists of four integrated service pillars: Pharmacovigilance Services (covering system management, QPPV, signal detection, PSMF, and PSUR), Regulatory Affairs (including pre/post-authorization support, Scientific Advice, and Orphan Drug Designation), Medical Writing (CTD modules, ERA, and scientific publications), and Clinical Trials Services (GCP-compliant pharmacovigilance, DSUR, SUSAR, and CSR). The VI.REL Master Class training program complements these services. The company operates with an international team serving clients in the SEE, USA, and Asian markets, and holds Marketing Authorizations for over 200 pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Brands

• VI.REL Master Class: Training courses offered in-person and online for individuals and companies, taught by top specialists in the pharmaceutical field.

Products and services

• Pharmacovigilance Services Comprehensive pharmacovigilance system management including QPPV services, ICSR management, signal detection, PSMF, PSUR, and risk management plans for pharmaceutical products from clinical development through post-marketing; intended for pharmaceutical companies and Marketing Authorization Holders needing outsourced or supplemental PV capacity.
• Regulatory Affairs Pre- and post-authorization regulatory affairs consulting including marketing authorization applications, Scientific Advice requests, Orphan Drug Designation, and interaction with regulatory agencies across the EEA, USA, and Asian markets; intended for pharmaceutical companies seeking or maintaining marketing authorizations.
• Medical Writing Professional scientific documentation services including Common Technical Document (CTD) modules, Environmental Risk Assessment (ERA), Addendum to Clinical Overview, scientific publications, and promotional material review; intended for pharmaceutical companies needing high-quality regulatory and scientific writing.
• Clinical Trials Services Pharmacovigilance services for clinical trials including Safety Management Plan, DSUR, SUSAR management, Clinical Study Report (CSR), and Clinical Trial Application (CTA) support in compliance with GCP standards; intended for clinical trial sponsors and pharmaceutical companies running GCP-compliant studies.
• VI.REL Master Class Professional training courses in pharmacovigilance and regulatory affairs for individuals and pharmaceutical companies, offered both in-person and online by field specialists; intended for pharmaceutical professionals and corporate teams seeking continuing education and certification.

Quantifiable outcome

• Over 200 Marketing Authorization Applications (MAAs/AIC) successfully registered
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Scale indicators4 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• Pharmalex: Mid-size European regulatory affairs, pharmacovigilance and quality compliance consultancy. Same service pillars (RA, PV, medical writing, clinical) as VI.REL but with broader geographic footprint and acquired scale.
• Arriello: European drug safety, pharmacovigilance, regulatory and quality consultancy serving biotech and specialty pharma. Overlaps directly with VI.REL's PV and regulatory affairs offering, with comparable boutique-mid positioning.
• PrimeVigilance: Specialized pharmacovigilance and risk management services provider offering QPPV, ICSR management, signal detection, and PSMF support to pharma and biotech clients across Europe. Closely comparable to VI.REL in service mix, though larger in scale.
• PharSafer: UK-headquartered pharmacovigilance, regulatory affairs and medical affairs consultancy serving small and mid-sized pharma. Direct peer offering the same QPPV-outsourcing and lifecycle regulatory services as VI.REL.
• Syner-G BioPharma: Pharmaceutical sciences consultancy offering regulatory affairs, medical writing, pharmacovigilance, and CMC services to emerging and mid-size pharma. Directly comparable operating model and client profile to VI.REL.
• Diamond Pharma Services: UK-based regulatory affairs, pharmacovigilance and medical affairs consultancy focused on EU and global submissions. Closely comparable boutique-mid specialist competing for the same client segment.

Emerging players

• Halloran Consulting Group: US-based life sciences consultancy with regulatory, quality, and clinical development offerings overlapping with VI.REL's regulatory affairs and medical writing services.
• Vigilare Biologics: Smaller emerging pharmacovigilance and drug safety consultancy with similar boutique service focus on MAH support, signal management and safety reporting.

Broad incumbents

• Parexel International: Large global CRO with comprehensive pharmacovigilance, regulatory affairs, and clinical development capabilities. Competes with VI.REL for large enterprise PV outsourcing mandates.
• IQVIA: Global Tier-1 CRO offering full-spectrum regulatory, PV, clinical, and commercial services. Overlaps with VI.REL on PV and regulatory affairs but as part of a vastly larger integrated platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VI.REL Pharma